ArticleRespirology case reports2026
Successful Introduction of Lorlatinib After Drug Eruption With Alectinib in ALK-Positive Lung Adenocarcinoma: A Case Report.
Article in Respirology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaplastic lymphoma kinase (ALK) fusion genes are detected in approximately 3%-5% of non-small cell lung cancers (NSCLC). Alectinib and lorlatinib are ALK tyrosine kinase inhibitors with established efficacy; however, their adverse event profiles differ. We report a 61-year-old man with recurrent ALK-positive lung adenocarcinoma who developed a grade 2 drug eruption consistent with fixed drug eruption during alectinib therapy. The rash resolved following drug discontinuation and corticosteroid treatment. Lorlatinib was subsequently initiated without recurrence of cutaneous toxicity. Apart from Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 dyslipidemia, no significant adverse events occurred, and partial response has been maintained for over 1 year. This case suggests that lorlatinib may be a feasible alternative in patients who develop cutaneous adverse reactions to alectinib, enabling continuation of targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.